Navigation
Skip to Content
Intro to Factbooks
Main Menu
Intro to Factbooks
Log Out
Executive Summary
Liferay DXP
Home
Bookmarks
Overview
Methodology
Glossary
Executive Summaries
Patient Journey
Overview
Disease Overview
Executive Summary
Key Data: Disease Overview, Classifications, Pathophysiology
Key Data: Epidemiology, Demographics, Unmet Needs
Symptom Onset
Executive Summary
Patient Experience
Key Data
Path to Diagnosis/Misdiagnosis
Executive Summary
Patient Experience
Key Data
Diagnosis & Staging
Executive Summary
Patient Experience
Key Data: Diagnosing Physicians & Suspecting Amyloidosis
Key Data: The Diagnosis Process
Current & Future Treatment
Executive Summary
Patient Experience
Key Data: Treatment Algorithm, Disease-Modifying Agents, Vyndaqel
Key Data: Supportive Care, Quantitative Survey, Future Disease-Modifying Treatments, Acoramidis
Disease Course (Progression)
Executive Summary
Key Data
Living with ATTR-CM
Executive Summary
Patient Experience
Key Data
Deep Dive
Disease Overview
Symptom Onset
Diagnosis & Staging
Current & Future Treatment
Disease Course (Progression)
Videos
Graphics
STAR PSv Forum Summary
PSv Forum Methodology
Insights & Implications
Liferay DXP
Overview
Download
Bookmark
Share
Success:
The bookmark has been added.
Success:
The bookmark has been removed.
Success:
The link has been copied.
Info:
Download started... Please wait
Success:
The file has been downloaded.
Error:
An error occurred while downloading. Please try again.
Wild-Type ATTR-CM Patient Journey — Overview of Key Stages
Japan
Points in
Italics
are specific to Japan
* CTS = Carpal Tunnel Syndrome, PPM = Permanent Pacemaker, ICD = Implanted Cardiac Defibrillator, CRT = Cardiac Resynchronization Therapy, SCD = Sudden Cardiac Death
REFERENCES
Yamada T, Takashio S, Arima Y, et al. Clinical characteristics and natural history of wild-type transthyretin amyloid cardiomyopathy in Japan. ESC Heart Fail. 2020;7(5):2829-2837. doi:10. 1002/ehf2. 12884
Previous page
Next page